Anne Helfen1, Annika Schnepel1, Jan Rieß1, Miriam Stölting1, Mirjam Gerwing1, Max Masthoff1, Thomas Vogl2, Johannes Roth2, Carsten Höltke1, Moritz Wildgruber1,3, Michel Eisenblätter1,4. 1. University Clinic of Radiology, Medical Faculty, University of Muenster and University Hospital Muenster, D-48149 Muenster, Germany. 2. Institute of Immunology, University of Muenster, 48149 Muenster, Germany. 3. Department for Radiology, University Hospital, LMU Munich, D-81377 Munich, Germany. 4. Department of Diagnostic and Interventional Radiology, Medical Center-University of Freiburg, D-79106 Freiburg, Germany.
Abstract
(1) Background: The prognosis of cancer is dependent on immune cells in the tumor microenvironment (TME). The protein S100A9 is an essential regulator of the TME, associated with poor prognosis. In this study, we evaluated early therapy effects on the TME in syngeneic murine breast cancer via S100A9-specific in vivo imaging. (2) Methods: Murine 4T1 cells were implanted orthotopically in female BALB/c mice (n = 59). Tumor size-adapted fluorescence imaging was performed before and 5 days after chemo- (Doxorubicin, n = 20), anti-angiogenic therapy (Bevacizumab, n = 20), or placebo (NaCl, n = 19). Imaging results were validated ex vivo (immunohistochemistry, flow cytometry). (3) Results: While tumor growth revealed no differences (p = 0.48), fluorescence intensities (FI) for S100A9 in Bevacizumab-treated tumors were significantly lower as compared to Doxorubicin (2.60 vs. 15.65 AU, p < 0.0001). FI for Doxorubicin were significantly higher compared to placebo (8.95 AU, p = 0.01). Flow cytometry revealed shifts in monocytic and T-cell cell infiltrates under therapy, correlating with imaging. (4) Conclusions: S100A9-specific imaging enables early detection of therapy effects visualizing immune cell activity in the TME, even before clinically detectable changes in tumor size. Therefore, it may serve as a non-invasive imaging biomarker for early therapy effects.
(1) Background: The prognosis of cancer is dependent on immune cells in the tumor microenvironment (TME). The protein S100A9 is an essential regulator of the TME, associated with poor prognosis. In this study, we evaluated early therapy effects on the TME in syngeneic murinebreast cancer via S100A9-specific in vivo imaging. (2) Methods:Murine 4T1 cells were implanted orthotopically in female BALB/c mice (n = 59). Tumor size-adapted fluorescence imaging was performed before and 5 days after chemo- (Doxorubicin, n = 20), anti-angiogenic therapy (Bevacizumab, n = 20), or placebo (NaCl, n = 19). Imaging results were validated ex vivo (immunohistochemistry, flow cytometry). (3) Results: While tumor growth revealed no differences (p = 0.48), fluorescence intensities (FI) for S100A9 in Bevacizumab-treated tumors were significantly lower as compared to Doxorubicin (2.60 vs. 15.65 AU, p < 0.0001). FI for Doxorubicin were significantly higher compared to placebo (8.95 AU, p = 0.01). Flow cytometry revealed shifts in monocytic and T-cell cell infiltrates under therapy, correlating with imaging. (4) Conclusions: S100A9-specific imaging enables early detection of therapy effects visualizing immune cell activity in the TME, even before clinically detectable changes in tumor size. Therefore, it may serve as a non-invasive imaging biomarker for early therapy effects.
Authors: Christina L Roland; Sean P Dineen; Kristi D Lynn; Laura A Sullivan; Michael T Dellinger; Leila Sadegh; James P Sullivan; David S Shames; Rolf A Brekken Journal: Mol Cancer Ther Date: 2009-06-30 Impact factor: 6.261
Authors: Rico D Bense; Christos Sotiriou; Martine J Piccart-Gebhart; John B A G Haanen; Marcel A T M van Vugt; Elisabeth G E de Vries; Carolien P Schröder; Rudolf S N Fehrmann Journal: J Natl Cancer Inst Date: 2016-10-13 Impact factor: 13.506
Authors: Takuya Osada; Gabriel Chong; Robert Tansik; Timothy Hong; Neil Spector; Rakesh Kumar; Herbert I Hurwitz; Inderjit Dev; Andrew B Nixon; H Kim Lyerly; Timothy Clay; Michael A Morse Journal: Cancer Immunol Immunother Date: 2008-01-10 Impact factor: 6.968
Authors: Anne Becker; Nils Große Hokamp; Stefanie Zenker; Fabian Flores-Borja; Katarzyna Barzcyk; Georg Varga; Johannes Roth; Christiane Geyer; Walter Heindel; Christoph Bremer; Thomas Vogl; Michel Eisenblaetter Journal: J Nucl Med Date: 2015-02-12 Impact factor: 10.057
Authors: Eva Källberg; Thomas Vogl; David Liberg; Anders Olsson; Per Björk; Pernilla Wikström; Anders Bergh; Johannes Roth; Fredrik Ivars; Tomas Leanderson Journal: PLoS One Date: 2012-03-28 Impact factor: 3.240